Showing 681 - 700 results of 105,975 for search '(( 10 mg decrease ) OR ( 5 ((((non decrease) OR (point decrease))) OR (a decrease)) ))', query time: 1.67s Refine Results
  1. 681
  2. 682

    Decreased cell stiffness after dissociation of intercellular adhesion. by Kristina Seiffert-Sinha (627059)

    Published 2014
    “…The corresponding cross section height measurements show a height decrease by slightly less than 100 nm (from ∼10 nm to −100 nm in the encircled area; lower panel); the arrow in the AFM images points to an intact intercellular connection before cutting (<b>E1</b>) and the disappearance thereof after cutting (<b>E2</b>). …”
  3. 683
  4. 684

    HFD induces LDs and decreases ER and mitochondria in nephrocytes. by Aleksandra Lubojemska (10746241)

    Published 2021
    “…(<b>E</b>) Low and high magnification views of pericardial nephrocytes (dotted outlines) from STD and HFD larvae, showing that HFD decreases mitochondria (marked with anti-ATP5A) and ER (marked with anti-KDEL) but increases LDs (marked with LipidTOX). …”
  5. 685
  6. 686
  7. 687
  8. 688

    Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

    Published 2022
    “…Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. …”
  9. 689

    Pharmacological Mechanism of the Non-hallucinogenic 5‑HT<sub>2A</sub> Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

    Published 2022
    “…Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. …”
  10. 690
  11. 691
  12. 692
  13. 693
  14. 694

    Serum concentrations of FGF23 at baseline and at week 40 in patients that achieved a serum phosphate concentration of <4.5 mg/dL and >4.5 mg/dL). by Cristian Rodelo-Haad (5607911)

    Published 2018
    “…Bars represent median and interquartile range. Serum iFGF23 decreased from 581.0 pg/mL (491.2–886.0) to 238.5 pg/mL (116.7–443.5) [median percent change of 63.8% (-75.2–5.40) in patients that achieved the target of phosphate <4.5 mg/dL. …”
  15. 695
  16. 696
  17. 697
  18. 698
  19. 699
  20. 700